Amlitelimab SAR445229 (formerly KY1005)

OX40L monoclonal antibody

Atopic Dermatitis, Phase 2

Cropped KY1005 Image

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. We believe this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In our Phase 1 clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. We believe the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation.

If you would like information on Sanofi’s managed access programs please see Managed Access Programs (MAPs) - Sanofi

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline